Biogen Investors Face Next Test With Pending Drug Patent Ruling
This article is for subscribers only.
Biogen Inc. investors should strap themselves in for a volatile week ahead of a key patent decision on its blockbuster multiple sclerosis drug.
A decision from the U.S. Patent Trial and Appeal Board, expected by February 6, could move shares up or down by 8%, options expiring February 7 show. Implied volatility is elevated near 70%, which compares to a three-month historical average of 46%.